Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$48.19

0.23 (0.48%)

, CLPBY

Coloplast

$0.00

(0.00%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55

Credit Suisse to hold a field trip

8th Annual European Healthcare Field Trip travels throughout London, England on December 8-12.

AZN

AstraZeneca

$48.19

0.23 (0.48%)

CLPBY

Coloplast

$0.00

(0.00%)

GNNDY

GN Store Nord

$0.00

(0.00%)

GSK

GlaxoSmithKline

$46.31

0.175 (0.38%)

IPSEY

Ipsen

$0.00

(0.00%)

LZAGY

Lonza

$0.00

(0.00%)

NVO

Novo Nordisk

$56.87

-0.08 (-0.14%)

NVS

Novartis

$93.01

0.22 (0.24%)

RHHBY

Roche

$0.00

(0.00%)

SNN

Smith & Nephew

$44.83

0.455 (1.03%)

SNY

Sanofi

$49.02

0.96 (2.00%)

SONVY

Sonova

$0.00

(0.00%)

  • 12

    Dec

  • 16

    Dec

  • 17

    Dec

AZN AstraZeneca
$48.19

0.23 (0.48%)

12/02/19
COWN
12/02/19
NO CHANGE
Target $55
COWN
Outperform
AstraZeneca price target raised to $55 from $48 at Cowen
Cowen analyst Steve Scala raised his price target on AstraZeneca to $55 from $48 as he believes its product momentum and high relative growth are not recognized. The analyst believes there is opportunity for upside as forecasts are below the company's guidance and its low relative exposure to the U.S. makes it less vulnerable to election rhetoric. Scala reiterated his Outperform rating on AstraZeneca shares.
11/15/19
GUGG
11/15/19
NO CHANGE
Target $228
GUGG
Buy
BeiGene price target raised to $228 from $205 at Guggenheim
Guggenheim analyst Michael Schmidt raised his price target for BeiGene (BGNE) to $228 from $205 saying FDA approval of Brukinsa over three months ahead of the action date provides additional validation of the company's strategy and ability to execute. He thinks Brukinsa's label in mantle cell lymphoma indicates a "potentially best-in-class" product profile with "nuanced differences" compared to AstraZeneca's (AZN) Calquence and "significantly better" than AbbVie's (ABBV) Imbruvica. The analyst maintains a Buy rating on BeiGene shares.
11/22/19
11/22/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Duke Energy (DUK) initiated with a Neutral at Mizuho. 2. Lancaster Colony (LANC) initiated with a Neutral at DA Davidson. 3. LendingTree (TREE) initiated with an Overweight at JPMorgan. 4. Zoom Video (ZM) initiated with a Buy at Guggenheim. 5. AstraZeneca (AZN) initiated with an Outperform at SVB Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/19
LEER
11/22/19
INITIATION
Target $57
LEER
Outperform
AstraZeneca initiated with an Outperform at SVB Leerink
SVB Leerink analyst Andrew Berens initiated coverage of AstraZeneca with an Outperform rating and $57 price target.
CLPBY Coloplast
$0.00

(0.00%)

07/19/19
LEHM
07/19/19
DOWNGRADE
LEHM
Equal Weight
Coloplast downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Hassan Al-Wakeel downgraded Coloplast to Equal Weight from Overweight and lowered his price target for the shares to 685 kroner from 700 kroner.
GNNDY GN Store Nord
$0.00

(0.00%)

09/10/19
JEFF
09/10/19
DOWNGRADE
JEFF
Underperform
GN Store Nord downgraded to Underperform from Buy at Jefferies
Jefferies analyst Kit Lee double downgraded GN Store Nord to Underperform from Buy.
10/31/19
GSCO
10/31/19
UPGRADE
GSCO
Buy
GN Store Nord upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Veronika Dubajova upgraded GN Store Nord to Buy from Neutral with a price target of 305 kroner, up from 262 kroner. The recent underperformance of the shares creates a "compelling" entry point, says the analyst.
GSK GlaxoSmithKline
$46.31

0.175 (0.38%)

11/21/19
11/21/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Kate McShane saying the retailer's Q3 results represented a positive step in rebuilding investor confidence around its execution capabilities and transformation strategy. 2. NorthWestern (NWE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jonathan Reeder saying the stock's price-to-earnings "looks too steep" at current valuation levels. 3. GlaxoSmithKline (GSK) upgraded to Buy from Neutral at UBS. 4. Kimco Realty (KIM) upgraded to Outperform from Sector Perform at Scotiabank. 5. Kulicke & Soffa (KLIC) upgraded to Buy from Neutral at DA Davidson analyst Thomas Diffely saying the company is now past its "trough quarter" and expects its "upcoming cyclical drivers" to generate revenue growth as "pockets of strength in the wirebonding market" serve as initial indicators of a broader industry recovery. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/03/19
MSCO
12/03/19
NO CHANGE
Target $100
MSCO
Equal Weight
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
Morgan Stanley analyst Matthew Harrison said he sees a high probability, or 75% odds, that Bluebird Bio (BLUE) shares will trade higher following the report of topline results from its KarMMa study of bb2121 as a fourth line or later therapy for the treatment of relapsed/refractory multiple myeloma, which are due by year-end. He said investors are focused on the median progression free survival delivered by the therapy as a gauge of its commercial viability versus other anti-BCMA CAR-T therapies in development at GlaxoSmithKline (GSK) and Bristol-Myers (BMY) in partnership with Regeneron (REGN). In a scenario where median PFS is greater than or equal to 11.5 months and overall response rate is greater than or equal to 85%, Harrison sees Bluebird shares having 20%-30% or more upside. If the median PFS is equal to or less than 9 months and ORR is below 80%, he thinks bb2121 would likely still be approvable, but sees shares down 10%-20%. In what he views as the most likely scenario - with mPFS of about 10 months and ORR of about 80% - Harrison sees 10%-20% upside in Bluebird shares. He keeps an Equal Weight rating and $100 price target on the stock.
12/02/19
LEER
12/02/19
INITIATION
Target $53
LEER
Outperform
GlaxoSmithKline initiated with an Outperform at SVB Leerink
SVB Leerink analyst Geoffrey Porges initiated coverage of GlaxoSmithKline with an Outperform rating and $53 price target.
11/21/19
UBSW
11/21/19
UPGRADE
UBSW
Buy
GlaxoSmithKline upgraded to Buy from Neutral at UBS
UBS upgraded GlaxoSmithKline to Buy from Neutral with a price target of 1900 pence, up from 1610 pence.
IPSEY Ipsen
$0.00

(0.00%)

03/04/19
BARD
03/04/19
DOWNGRADE
Target $27
BARD
Neutral
Baird downgrades Clementia to Neutral on lack of data ahead of deal closing
As reported previously, Baird analyst Madhu Kumar downgraded Clementia Pharmaceuticals (CMTA) to Neutral from Outperform. The analyst cited a likely lack of chronic dosing results pre-deal closure with Ipsen (IPSEY). The timing of the deal vote versus MOVE interim data provides little room for upside, said Kumar, who has a $27 on price target on Clementia Pharmaceuticals shares.
04/24/19
WELS
04/24/19
NO CHANGE
Target $189
WELS
Outperform
Ipsen commentary a positive for Allergan's Botox business, says Wells Fargo
Wells Fargo analyst David Maris notes that Ipsen (IPSEY) reported Q1 results and reported overall sales of Dysport of approximately EUR$94M, up 10% over Q1 2018, citing strong performance in the U.S. in both therapeutics and aesthetics. The analyst believes the commentary from Ipsen is a positive read through to Allergan (AGN) and its key franchise, Botox, in the near-future and over the longer-term. Allergan has cited market expansion as a tailwind for Botox in the past as well, and Ipsen's commentary reiterates that viewpoint, he adds. Maris reiterates an Outperform rating and a $189 price target on Allergan's shares.
12/09/19
LEHM
12/09/19
DOWNGRADE
Target $90
LEHM
Equal Weight
Ipsen downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Emily Field downgraded Ipsen to Equal Weight from Overweight with a EUR 90 price target. The partial clinical hold placed on the company's trials of palovarotene in children will significantly delay the drug's filing and approval in fibrodysplasia ossificans progressiva, the stock's most important catalyst for 2020, Field tells investors in a research note.
05/20/19
JPMS
05/20/19
UPGRADE
JPMS
Neutral
Ipsen upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Richard Vosser upgraded Ipsen to Neutral from Underweight with a price target of EUR 110.
LZAGY Lonza
$0.00

(0.00%)

01/31/19
BOFA
01/31/19
DOWNGRADE
BOFA
Neutral
Lonza downgraded to Neutral from Buy at BofA/Merrill
NVO Novo Nordisk
$56.87

-0.08 (-0.14%)

11/19/19
LEER
11/19/19
NO CHANGE
Target $30
LEER
Outperform
Dicerna price target raised to $30 from $26 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna (DRNA) to $30 from $26 and maintained an Outperform rating after the company announced a collaboration with Novo Nordisk (NVO) to develop candidates for liver-related cardiometabolic diseases. In a research note to investors, Foroohar says that while Dicerna's stock has traded up about 30% since the announcement of a partnership with Roche (RHHBY), it remains undervalued.
11/19/19
RHCO
11/19/19
NO CHANGE
Target $28
RHCO
Buy
Dicerna price target raised to $28 from $24 at SunTrust
SunTrust analyst Robyn Karnauskas raised her price target on Dicerna (DRNA) to $28 and kept her Buy rating, saying the company's collaboration with Novo Nordisk (NVO) on liver-related cardiometabolic disease candidates demonstrate its ability to participate in larger deals with upside optionality. The analyst believes that Dicerna can become a "larger platform play" over the long term, comparable to Ionis Pharma (IONS) and Alnylam (ALNY).
11/22/19
PART
11/22/19
DOWNGRADE
PART
Hold
Novo Nordisk downgraded to Hold from Buy at Pareto
Pareto analyst Johan Unnerus downgraded Novo Nordisk to Hold from Buy with a price target of 385 kroner.
11/19/19
HCWC
11/19/19
NO CHANGE
Target $30
HCWC
Buy
Dicerna price target raised to $30 from $22 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Dicerna Pharmaceuticals (DRNA) to $30 from $22 after the company after announced a new strategic alliance with Novo Nordisk (NVO). The analyst sees "favorable deal terms embedded with optionality." He continues to view Dicerna as a "core, pure-play holding" in the greater nucleic acid therapy space and reiterates a Buy rating on the shares.
NVS Novartis
$93.01

0.22 (0.24%)

12/06/19
CANT
12/06/19
INITIATION
Target $34
CANT
Overweight
Gossamer Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle initiated coverage of Gossamer Bio (GOSS) with an Overweight rating and $34 price target. The analyst sees a "compelling" setup into 2020. While the Luster data from Novartis (NVS) has significant stock moving potential for Gossamer, with upside potential of 75%-100% versus downside of 25%-50%, GB002 for pulmonary arterial hypertension could be a $2B peak sales opportunity with potential de-risking in the first half of 2020 "that deserves more focus," Merle tells investors in a research note.
11/25/19
OPCO
11/25/19
DOWNGRADE
Target $85
OPCO
Perform
The Medicines Co. downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Jay Olson downgraded The Medicines Co. (MDCO) to Outperform from Perform with a price target of $85, up from $68, after it agreed to be acquired by Novartis (NVS) for $9.7B. After months of impressive data presentations for inclisiran and media reports of alleged negotiations with potential acquirers, Olson says that this this deal announcement brings welcomed news to The Medicines Co. investors who were patient enough to "weather an exciting ride."
11/25/19
BARD
11/25/19
UPGRADE
Target $70
BARD
Outperform
Arrowhead upgraded to Outperform after Medicines Company takeover at Baird
As previously reported, Baird analyst Madhu Kumar upgraded Arrowhead Pharmaceuticals (ARWR) to Outperform from Neutral with a price target of $70, up from $39, after Medicines Company (MDCO) announced a definitive agreement to be acquired by Novartis (NVS). That deal forces Kumar to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease, the analyst tells investors. Given the early positive efficacy for Arrowhead's ANGPTL3 and APOC3 RNAi drugs presented at the American Heart Association meeting, Kumar believes these programs have "the chance to dominate the ANGPTL3 and APOC3 landscapes," though cautions both are "quite early."
12/04/19
BOFA
12/04/19
NO CHANGE
Target $104
BOFA
Buy
BofA/Merrill recommends investors buy Novartis on new product growth
BofA/Merrill analyst Graham Parry keeps his Buy rating and CHF104 price target on Novartis in spite of lowering his FY20 EPS view to $5.64 from $5.92 to reflect the dilution from its Medicines Co acquisition and expected completion of the US generics divestment to Aurobindo. The analyst cites the company's expected new launches and forecasts "premium growth" from its new products, saying its sales are set to rise about 7% in 2019-2022 thanks to its "16 key growth products and Pharma margin expansion" to 37.1% from 33.3% this year.
RHHBY Roche
$0.00

(0.00%)

11/01/19
LEER
11/01/19
NO CHANGE
Target $26
LEER
Outperform
Dicerna price target raised to $26 from $22 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna Pharmaceuticals (DRNA) to $26 from $22 saying the terms for the company's partnership with Roche (RHHBY) to develop and commercialize DCR-HBVS are "quite favorable." Dicerna will receive a $200M upfront payment, up to $1.47B in potential milestones, and up to mid-teens royalties on future sales. The transaction is "meaningfully validating" for Dicerna's strategy for large population indications, Foroohar tells investors in a research note. With shares trading at an implied enterprise value "materially below" the pre-deal value, investors should begin to appreciate the scope of the potential partnership opportunities, says the analyst. He keeps an Outperform rating on Dicerna.
11/01/19
HCWC
11/01/19
NO CHANGE
Target $22
HCWC
Buy
Dicerna HBV deal earlier, on better terms than expected, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce affirmed his Buy rating on Dicerna Pharmaceuticals (DRNA) shares after the companpy announced a collaboration and licensing agreement with Roche (RHHBY) for the worldwide development and commercialization the company's lead asset for the treatment of hepatitis B virus, or HBV. While he has long anticipated "a large HBV deal," the collaboration with Roche is earlier, and with better economics, than Arce had expected, the analyst tells investors. He maintains a $22 price target on Dicerna shares.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
William Blair says Ionis fairly valued on Spinraza headwinds
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating and $58 fair value estimate. Spinraza, which is marketed by Biogen (BIIB), generates about $2B in revenue per year and has revolutionized the treatment of spinal muscular atrophy, but its long-term growth potential faces headwinds, Minter tells investors in a research note. The analyst anticipates the recent approval of Novartis's (NVS) Zolgensma, an SMA gene therapy, will erode Spinraza's market share of new-start type-1 SMA patients. But more concerning, according to Minter, is the potential 2020 U.S. approval of Roche's (RHHBY) risdiplam, which he believes could erode Spinraza's total market share of type-2/3 patients given a more favorable oral route of delivery. The analyst sees Ionis shares as fairly valued at current levels given the near-term headwinds for its commercial franchise.
SNN Smith & Nephew
$44.83

0.455 (1.03%)

11/21/19
SBSH
11/21/19
INITIATION
SBSH
Buy
Smith & Nephew initiated with a Buy at Citi
Citi analyst Kate Kalashnikova initiated coverage of Smith & Nephew with a Buy rating and price target of 1,970 pence. At a 25% discount to the medical technology sector, the shares are trading at an attractive entry point, Kalashnikova tells investors in a research note. The analyst also highlights Smith & Nephew's acquisition potential to boost its growth.
11/12/19
BERN
11/12/19
INITIATION
BERN
Outperform
Smith & Nephew re-initiated with an Outperform at Bernstein
Bernstein analyst Lisa Bedell Clive re-initiated coverage of Smith & Nephew with an Outperform rating and 19 pounds price target. The analyst re-launched coverage of European Medical Device & Services and favors companies that are dominant in their field, believing barriers to entry and importance of scale are increasing.
11/21/19
11/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Noble Energy (NBL) initiated with a Buy at MKM Partners. 2. Smith & Nephew (SNN) initiated with a Buy at Citi. 3. Dell Technologies (DELL) initiated with a Neutral at Nomura Instinet. 4. Virgin Galactic (SPCE) initiated with an Outperform at Credit Suisse. 5. Alector (ALEC) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/22/19
ADAM
10/22/19
NO CHANGE
Target $52
ADAM
Buy
Smith & Nephew CEO resignation a surprise, more cautious view, says Canaccord
Canaccord analyst Kyle Rose said the surprise departure of the Smith & Nephew CEO following Q3 results has made him incrementally cautious on the name. He said he is disappointed in the move given how quickly CEO Nawana changed the firm's culture as well as the company's execution. Reports say the departure was due to compensation issues and the disparity in total compensation at Smith & Nephew versus U.S. peers. Given the stocks performance and the CEO leaving, the analyst would not be surprised to see investors take profits. Rose maintained his Buy rating and $52 price target on Smith & Nephew shares.
SNY Sanofi
$49.02

0.96 (2.00%)

12/11/19
GABE
12/11/19
DOWNGRADE
GABE
Hold
Lexicon downgraded to Hold on valuation at Gabelli
As previously reported, Gabelli analyst Kevin Kedra downgraded Lexicon (LXRX) to Hold from Buy based on valuation following the $2.00 per share, or roughly 60%, run-up in the stock over the past week. While the stock's recent strength brings the price more in-line with his 2020 private market value estimate of $5.00 per share, Kedra said Sanofi's (SNY) recent announcement that it is shifting focus away from diabetes gives him added confidence that the dissolution of the sotagliflozin partnership was more about Sanofi's strategy than any potential problems or red flags with the Lexicon Phase 3 program in type 2 diabetes. He still has confidence in CEO Lonnel Coats' ability to find another favorable partnership for sotagliflozin, Kedra added.
12/11/19
LEER
12/11/19
DOWNGRADE
Target $68
LEER
Market Perform
Synthorx downgraded to Market Perform at SVB Leerink following Sanofi deal
SVB Leerink analyst Daina Graybosch downgraded Synthorx (THOR) to Market Perform from Outperform with a price target of $68, up from $24, following Sanofi's (SNY) acquisition announcement. Given the deal size and current competitive landscape of interleukin-2 based therapies, Graybosch tells investors that she sees limited likelihood of a competing offer.
12/10/19
HCWC
12/10/19
DOWNGRADE
Target $68
HCWC
Neutral
Synthorx downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay downgraded Synthorx (THOR) to Neutral from Buy with a price target of $68, up from $30. The analyst cites the takeover by Sanofi (SNY) for the downgrade.
12/06/19
LEHM
12/06/19
DOWNGRADE
Target $75
LEHM
Underweight
Barclays downgrades Sanofi to Underweight on 'multiple' Pharma challenges
Barclays analyst Emmanuel Papadakis downgraded Sanofi to Underweight from Equal Weight with a EUR 75 price target. The analyst continues to see "multiple challenges" for the company's Pharma business across several major franchises, and "limited scope" for upside from present share levels even on a sum-of-the-parts basis. Sanofi's "pipeline deficiency" has no easy or cheap fix, Papadakis tells investors in a research note.
SONVY Sonova
$0.00

(0.00%)

09/10/19
JEFF
09/10/19
UPGRADE
JEFF
Buy
Sonova upgraded to Buy from Hold at Jefferies
Jefferies analyst Kit Lee upgraded Sonova to Buy from Hold.
10/31/19
GSCO
10/31/19
DOWNGRADE
GSCO
Sell
Sonova downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Veronika Dubajova downgraded Sonova to Sell from Neutral with a price target of 193 francs. The analyst views the recent share outperformance as unwarranted and sees downside risk to consensus estimates.

TODAY'S FREE FLY STORIES

ITRM

Iterum Therapeutics

$3.29

-1.21 (-26.89%)

05:44
01/21/20
01/21
05:44
01/21/20
05:44
Downgrade
Iterum Therapeutics rating change  »

Iterum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDE

Coeur Mining

$5.86

-1.17 (-16.64%)

05:41
01/21/20
01/21
05:41
01/21/20
05:41
Downgrade
Coeur Mining rating change  »

Coeur Mining downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LGF.B

Lionsgate

$10.32

-0.305 (-2.87%)

05:39
01/21/20
01/21
05:39
01/21/20
05:39
Downgrade
Lionsgate rating change  »

Lionsgate downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

USB

U.S. Bancorp

$55.33

0.14 (0.25%)

05:36
01/21/20
01/21
05:36
01/21/20
05:36
Downgrade
U.S. Bancorp rating change  »

U.S. Bancorp downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 15

    Apr

CHGG

Chegg

$43.36

0.64 (1.50%)

05:34
01/21/20
01/21
05:34
01/21/20
05:34
Recommendations
Chegg analyst commentary  »

Chegg price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

  • 19

    Feb

ROKU

Roku

$130.35

-0.76 (-0.58%)

05:33
01/21/20
01/21
05:33
01/21/20
05:33
Hot Stocks
Roku announces arrival in Brazil through partnership with AOC »

Roku announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

RNR

RenaissanceRe

$193.19

0.235 (0.12%)

05:32
01/21/20
01/21
05:32
01/21/20
05:32
Initiation
RenaissanceRe initiated  »

RenaissanceRe initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Feb

RE

Everest Re

$279.96

2.455 (0.88%)

05:31
01/21/20
01/21
05:31
01/21/20
05:31
Initiation
Everest Re initiated  »

Everest Re initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

COST

Costco

$304.68

1.83 (0.60%)

05:31
01/21/20
01/21
05:31
01/21/20
05:31
Upgrade
Costco rating change  »

Costco upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 05

    Mar

HIG

Hartford Financial

$61.20

0.925 (1.53%)

05:30
01/21/20
01/21
05:30
01/21/20
05:30
Initiation
Hartford Financial initiated  »

Hartford Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

UBS

UBS

$13.13

-0.06 (-0.45%)

05:29
01/21/20
01/21
05:29
01/21/20
05:29
Hot Stocks
UBS agrees to sell majority stake in UBS Fondcenter to Clearstream »

UBS Group AG and UBS AG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

AIG

AIG

$52.88

0.52 (0.99%)

05:29
01/21/20
01/21
05:29
01/21/20
05:29
Initiation
AIG initiated  »

AIG initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$140.72

1.85 (1.33%)

05:28
01/21/20
01/21
05:28
01/21/20
05:28
Initiation
Travelers initiated  »

Travelers initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CB

Chubb

$153.67

1 (0.66%)

05:28
01/21/20
01/21
05:28
01/21/20
05:28
Initiation
Chubb initiated  »

Chubb initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

PGR

Progressive

$76.29

0.85 (1.13%)

05:27
01/21/20
01/21
05:27
01/21/20
05:27
Initiation
Progressive initiated  »

Progressive initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALL

Allstate

$117.54

1.39 (1.20%)

05:26
01/21/20
01/21
05:26
01/21/20
05:26
Initiation
Allstate initiated  »

Allstate initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Feb

  • 13

    Mar

UBS

UBS

$13.13

-0.06 (-0.45%)

05:26
01/21/20
01/21
05:26
01/21/20
05:26
Hot Stocks
UBS targeting RoCET1 of 12%-15% om 2020-2022 »

UBS provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

WLTW

Willis Towers Watson

$204.95

0.76 (0.37%)

05:25
01/21/20
01/21
05:25
01/21/20
05:25
Initiation
Willis Towers Watson initiated  »

Willis Towers Watson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 28

    Jan

  • 06

    Feb

  • 10

    Feb

  • 11

    Feb

  • 11

    Feb

MMC

Marsh & McLennan

$114.11

1.32 (1.17%)

05:24
01/21/20
01/21
05:24
01/21/20
05:24
Initiation
Marsh & McLennan initiated  »

Marsh & McLennan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

AON

Aon plc

$211.77

1.66 (0.79%)

05:24
01/21/20
01/21
05:24
01/21/20
05:24
Initiation
Aon plc initiated  »

Aon plc initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 26

    Feb

UBS

UBS

$13.13

-0.06 (-0.45%)

05:24
01/21/20
01/21
05:24
01/21/20
05:24
Earnings
UBS reports Q4 EPS 19c, one estimate 18c »

Reports Q4 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

PING

Ping Identity

$25.68

-0.34 (-1.31%)

05:19
01/21/20
01/21
05:19
01/21/20
05:19
Downgrade
Ping Identity rating change  »

Ping Identity downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNG

RingCentral

$192.99

2.36 (1.24%)

, AVYA

Avaya

$12.97

(0.00%)

05:17
01/21/20
01/21
05:17
01/21/20
05:17
Upgrade
RingCentral, Avaya rating change  »

RingCentral upgraded to…

RNG

RingCentral

$192.99

2.36 (1.24%)

AVYA

Avaya

$12.97

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$46.57

-0.37 (-0.79%)

05:15
01/21/20
01/21
05:15
01/21/20
05:15
Earnings
Logitech backs FY20 revenue guidance of mid to high single-digit growth »

Backs FY20 non-GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

GLNCY

Glencore

$0.00

(0.00%)

05:14
01/21/20
01/21
05:14
01/21/20
05:14
Upgrade
Glencore rating change  »

Glencore upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.